The Alarming Surge of Counterfeit Oncology Medications in Bengaluru

A recent investigation by India Today has uncovered a disturbing trend: more than 90 hospitals in Bengaluru are being scrutinised for allegedly dispensing fake cancer drugs at a 50 % discount. The revelations have sent shockwaves through the medical community, patient advocacy groups, and regulatory bodies, raising urgent questions about drug safety, supply‑chain integrity, and the ethical responsibilities of healthcare institutions.

---

What the Investigation Revealed

• Scale of the issue: Over 90 private and public hospitals across the city were flagged after a whistle‑blower alerted authorities to suspicious procurement records.
• Discount deception: The purported discounts, advertised as a benevolent gesture for cancer patients, turned out to be a ruse—many of the discounted batches failed laboratory tests for potency and purity.
• Regulatory response: The Karnataka State Drug Control Department (KSDCD) has launched a city‑wide audit, seizing thousands of boxes of suspect medication and suspending licences of several pharmacies.
• Patient impact: Preliminary data suggests hundreds of oncology patients may have received sub‑standard treatment, potentially compromising therapeutic outcomes and survival rates.

---

How Counterfeit Drugs Slip Into the System

The counterfeit drug trade thrives on complex supply‑chain loopholes:

1. Unverified distributors – Small, unregistered wholesalers often act as middlemen, buying bulk consignments from overseas manufacturers with lax oversight.
2. Fake certifications – Bogus certificates of analysis are presented to hospital procurement teams, who, under pressure to cut costs, accept them at face value.
3. Inadequate testing – Many hospitals lack in‑house pharmacovigilance labs, relying instead on third‑party labs that may be compromised or under‑resourced.

Regulatory Gaps and the Way Forward

The KSDCD’s swift action underscores the need for systemic reforms:

• Mandatory third‑party testing for all oncology drugs before they enter hospital pharmacies.
• Real‑time digital tracking of drug batches using blockchain or QR‑code verification, enabling instant authenticity checks.
• Strengthened whistle‑blower protections to encourage insiders to report irregularities without fear of retaliation.
• Public awareness campaigns that educate patients on how to verify drug authenticity, such as checking batch numbers against official portals.

Voices from the Frontline

"When you are battling cancer, you cannot afford a second‑guess. The idea that a hospital could sell us fake medicine is a betrayal of trust," says Radhika Sharma, a survivor of breast cancer who was treated at one of the flagged hospitals.

"We need a transparent, auditable supply chain. It’s not just about catching the bad actors; it’s about building a system that prevents them from entering in the first place," notes Dr. Arvind Patel, an oncologist and member of the Indian Association of Medical Oncology.

---

Takeaways for Patients and Practitioners

• Verify before you trust: Always ask for batch numbers and cross‑check them on the Central Drugs Standard Control Organization (CDSCO) portal.
• Demand transparency: Hospitals should disclose their drug procurement policies and allow patients to see certificates of analysis.
• Report anomalies: Any suspicion of counterfeit medication should be reported immediately to the Karnataka State Drug Control Department or the National Consumer Helpline.

The Bengaluru episode is a stark reminder that affordability should never compromise safety. As regulators tighten the net and hospitals adopt stricter verification protocols, the hope is that patients will receive the life‑saving treatments they deserve—free from the shadow of counterfeit drugs.

---

Stay informed, stay vigilant, and demand accountability. The fight against cancer is already hard enough; counterfeit drugs should never add to the burden.

---

Original Reporting & Source: India Today Top Stories